Organization
Celgene Corporation, Summit
3 abstracts
Abstract
52-WEEK EFFICACY AND SAFETY OF APREMILAST AND SWITCH FROM ETANERCEPT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: RESULTS FROM THE LIBERATE STUDY Org: SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, Southern California Dermatology, Santa Ana, United States, Skin Centre for Dermatology and Probity Medical Research, Peterborough, Canada, Celgene Corporation, Summit,
Abstract
APREMILAST IS ASSOCIATED WITH LONG-TERM (4-YEAR) DAS-28 (CRP) REMISSION AND IMPROVEMENTS IN SKIN DISEASE: RESULTS FROM A PHASE III STUDY IN DMARD/BIOLOGIC-EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS Org: University Hospital Southampton, Southampton, United Kingdom, INIBIC-Hospital Universitario A Coruña, Galicia, Spain, Bakersfield Dermatology, Bakersfield, Celgene Corporation, Summit, University of Massachusetts Medical School, Worcester, United States,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENT IN FATIGUE IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Toronto Western Research Institute, Toronto, Canada, University Hospital Southampton, Southampton, United Kingdom, Clinical Research Centre Ltd, Tartu, Estonia, University Paris Diderot, Paris, France, University of New South Wales, Kogarah, Australia,